Integrating Durvalumab and Atezolizumab Into Neoadjuvant and Adjuvant Sequencing Strategies for Resectable NSCLC | AJMC
Integrating Durvalumab and Atezolizumab Into Neoadjuvant an…
2 weeks ago
ajmc.com
Tips for Managing NSCLC Patients on Durvalumab Therapy | OncLive
Tips for Managing NSCLC Patients on Durvalumab Therapy | OncLive
Mar 13, 2018
onclive.com
Real-World Use of Durvalumab Tremelimumab in Advanced HCC | OncLive
Real-World Use of Durvalumab Tremelimumab in Advanced HCC …
Oct 28, 2022
onclive.com
A New Immunotherapy for Bladder Cancer
A New Immunotherapy for Bladder Cancer
Dec 29, 2019
aacr.org
Dr. Langer on the Benefit of Durvalumab in Stage III NSCLC | OncLive
Dr. Langer on the Benefit of Durvalumab in Stage III NSCLC | O…
May 29, 2019
onclive.com
The FDA has expanded its approval of Imfinzi® (durvalumab), to include stage III non-small cell lung cancer patients. The immunotherapy was approved for bladder cancer last year, but Moffitt’s Dr. Scott Antonia saw the potential of Imfinzi as a treatment option for lung cancer patients. He launched a global clinical trial with more than 700 patients and found the therapy made a big difference in survival for this group of patients. http://ow.ly/bwij30ivPPd | Moffitt Cancer Center
0:34
The FDA has expanded its approval of Imfinzi® (durvalumab), to includ…
4.8K viewsFeb 20, 2018
FacebookMoffitt Cancer Center
ASCO 2021 Updates from the PACIFIC Trial: Five-Year Survival Outcomes with Durvalumab After CRT in Unresectable Stage III NSCLC
ASCO 2021 Updates from the PACIFIC Trial: Five-Year Survival …
268 viewsNov 11, 2021
vumedi.com
Durvalumab in LS-SCLC: Exploring Phase 3 ADRIATIC Trial Outcome…
3 weeks ago
onclive.com
Durvalumab in Stage III NSCLC Based on Performance Status | On…
Jul 13, 2020
onclive.com
PACIFIC Trial: Durvalumab Following Chemotherapy for Stag…
Jul 13, 2020
onclive.com
Dr. Powles Discusses the Future of Durvalumab in Bladder Cancer | O…
Mar 8, 2017
onclive.com
ESMO 2024 Insights: CCTG BR.31 - Adjuvant Durvalumab in Complete…
26 viewsOct 21, 2024
vumedi.com
PACIFIC Trial: Durvalumab for Stage 3 NSCLC | OncLive
Sep 28, 2017
onclive.com
DUO-E Trial: Durvalumab With or Without Olaparib for Endometrial …
Jan 6, 2022
targetedonc.com
TOPAZ-1: Durvalumab Doublet Chemotherapy in Advanced Biliar…
Oct 26, 2022
onclive.com
Pre-Treatment Guidelines for Patients Undergoing Durvalumab …
6 months ago
archyde.com
Evaluating the Cost-Effectiveness of Immunotherapy in Lung Cancers | …
2 weeks ago
cancernetwork.com
Dr. Balar on Results of Durvalumab Plus Tremelimumab in Bladder Ca…
Apr 17, 2018
onclive.com
Updated Overall Survival from the Phase 3 TOPAZ-1 Study of Durval…
Jan 10, 2023
onclive.com
Dr. Balar on Impact of Durvalumab Plus Tremelimumab in Bladder Ca…
May 10, 2018
onclive.com
Dr. Sonpavde on Fixed-Dose Durvalumab and Tremelimumab S…
Feb 10, 2018
onclive.com
Dr. Siefker-Radtke on FDA Approval of Durvalumab in Bladder Cancer …
May 2, 2017
onclive.com
3:07
The Use of Durvalumab in Locally Advanced NSCLC
283 viewsApr 16, 2018
YouTubeTargeted Oncology
Dr. Joshi Discusses Durvalumab and Radiation Therapy in Bladder …
Feb 9, 2018
onclive.com
6:29
Durvalumab ( Imfinzi ) for HCC
321 viewsAug 15, 2024
YouTubePharmComm
52:55
Immunotherapy Nightmare - Imfinzi/Durvalumab Experience - L…
5.1K viewsAug 31, 2024
FacebookJenny Appleford
Durvalumab: A Review in Extensive-Stage SCLC
Jan 27, 2020
nih.gov
Multidisciplinary Approaches to Managing LS-SCLC: Immunothera…
8 months ago
onclive.com
Durvalumab Tolerability in Non–Small Cell Lung Cancer
1.5K viewsFeb 25, 2020
YouTubeTargeted Oncology
See more videos
Static thumbnail place holder